252 related articles for article (PubMed ID: 17618321)
1. Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies.
Bolwell BJ; Pohlman B; Rybicki L; Sobecks R; Dean R; Curtis J; Andresen S; Koo A; Mineff V; Kalaycio M; Sweetenham JW
Bone Marrow Transplant; 2007 Sep; 40(5):437-41. PubMed ID: 17618321
[TBL] [Abstract][Full Text] [Related]
2. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma.
Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C
Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835
[TBL] [Abstract][Full Text] [Related]
5. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation.
Pavone V; Gaudio F; Console G; Vitolo U; Iacopino P; Guarini A; Liso V; Perrone T; Liso A
Bone Marrow Transplant; 2006 Apr; 37(8):719-24. PubMed ID: 16518434
[TBL] [Abstract][Full Text] [Related]
6. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
7. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
8. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma.
Tomblyn M; Burns LJ; Blazar B; Wagner J; Lee C; Rogers T; McGlave P; Miller JS; Weisdorf DJ
Bone Marrow Transplant; 2007 Jul; 40(2):111-8. PubMed ID: 17530003
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
[TBL] [Abstract][Full Text] [Related]
10. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation.
Allan DS; Keeney M; Howson-Jan K; Popma J; Weir K; Bhatia M; Sutherland DR; Chin-Yee IH
Bone Marrow Transplant; 2002 Jun; 29(12):967-72. PubMed ID: 12098064
[TBL] [Abstract][Full Text] [Related]
11. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK; Kaufman J
Transfusion; 2007 Apr; 47(4):629-35. PubMed ID: 17381621
[TBL] [Abstract][Full Text] [Related]
13. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP
Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718
[TBL] [Abstract][Full Text] [Related]
15. Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation.
Demirkazik A; Kessinger A; Armitage JO; Bierman PJ; Lynch J; Vose J; Chan W; Sharp JG
Bone Marrow Transplant; 2001 Jul; 28(2):207-12. PubMed ID: 11509940
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.
Ballova V; Ladicka M; Vranovsky A; Lakota J
Neoplasma; 2008; 55(5):428-36. PubMed ID: 18665754
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma.
Mollee P; Pereira D; Nagy T; Song K; Saragosa R; Keating A; Crump M
Bone Marrow Transplant; 2002 Sep; 30(5):273-8. PubMed ID: 12209348
[TBL] [Abstract][Full Text] [Related]
18. Mobilization of peripheral blood stem cells for autologous transplantation patients with hematological malignancies: Influence of disease, mobilization method, age and sex.
Zhang C; Chen X; Zhang X; Gao L; Kong P; Wang Q; Peng X; Liu H
Transfus Apher Sci; 2008 Aug; 39(1):21-8. PubMed ID: 18599353
[TBL] [Abstract][Full Text] [Related]
19. ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
Akhtar S; Tbakhi A; Humaidan H; El Weshi A; Rahal M; Maghfoor I
Bone Marrow Transplant; 2006 Feb; 37(3):277-82. PubMed ID: 16400345
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
